Clinical profile of recent progressive illnesses in patients with mucormycosis: a comprehensive analysis

Authors

  • Shrikant Sharma Department of Medicine, SMS Medical College, Jaipur, Rajasthan, India
  • Mukul Singhal Department of Medicine, SMS Medical College, Jaipur, Rajasthan, India
  • Sudhir Bhandari Department of Medicine, SMS Medical College, Jaipur, Rajasthan, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20220983

Keywords:

Mucormycosis, Steroids, Oxygen, COVID-19, Remdesivir, Hospitalisation

Abstract

Background: The COVID-19 pandemic, in its omnipresence, descended an unprecedented blow on the reeling facilities nationwide, which at its stabilising junction posed another threat – mucormycosis. Potentially immunodeficient cases, diabetes and excessive rampancy of steroids propagated this neo-epidemic, currently challenging the fretting mortality rate. Aim of the study was to analyse the clinical profile elaborating the recent illnesses and progression in patients admitted with mucormycosis in a dedicated ‘mucor-care’ centre.

Methods: Total 195 admitted patients were evaluated based on their COVID protocol management and oxygen therapy administered with special emphasis on hygiene maintenance in view of mask support, oral care and hospitalisation course with duration and medications provided. Type and duration of glucocorticoids, injectable or oral, dispensed to the patients were duly logged and analysed.

Results: Half cases (50%) were found COVID reverse transcriptase-polymerase chain reaction (RT-PCR) positive with 69% patients suffering from moderate ailment and above. Patients averaged 25-30 days at onset of post-COVID mucormycosis symptomatology with 78% (172) cases having h/o hospitalisation. 90% patients required oxygen therapy in variable magnitudes with meagre 38% receiving ‘remdesivir’ complete course dosages. Despite being prudent, 58% did not maintain adequate sanitation while 72% denied having oxygen humidified. Steroids were pivotal with 84% affirmative prevalence; dexamethasone being commonest, averaging 15 days of therapy, which supplementing immune-compromised modalities, promulgated this epidemic.

Conclusions: The deadly trinity of diabetes, rampancy of steroids in a background of COVID-19 caused havoc in recent times. Only astute usage of resources and prudent education can curb this menace in a better way.

 

Author Biography

Shrikant Sharma, Department of Medicine, SMS Medical College, Jaipur, Rajasthan, India

General Medicine Resident ( PG )

References

Frater JL, Hall GS, Procop GW. Histologic features of zygomycosis: Emphasis on perineural invasion and fungal morphology. Arch Pathol Lab Med. 2001;125:375-8.

Indian Council of Medical Research. Mucormycosis. Available at: www.icmr.gov.in/mucrmycosis/press-release. Accessed on 21 May 2021.

COVID19 India. Available at: www.COVID19india. org/rajasthan-newsrelease. Accessed on 21 May 2021.

Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA Schaufele RL, et al. Epidemiology and outcome of zygomycosis: A review of 929 reported cases. Clin Infect Dis. 2005;41:634-53.

Chakrabarti A, Das A, Sharma A, Panda N, Das S, Gupta KL, Sakhuja V. Ten Years’ Experience in Zygomycosis at a Tertiary Care Centre in India. J Infect. 2001;42:261-6.

Paltauf A. Mycosis mucorina: Ein Beitrag zur Kenntnis der menschilchen Fadenpiltzer-krankungen. Virchows Arch Pathol Anat. 1885;102:543-64.

Mandal J, Shivaprakash MR, George VK, Tarai B, Rao P, Panda N, et al. The rising trend of invasive zygomycosis in patients with uncontrolled diabetes mellitus. Med Mycol. 2006;44:335-42.

Mehta S, Pandey A. Rhino-orbital mucormycosis associated with COVID-19. Cureus. 2020;12(9):e10726.

Prakash H, Chakrabarti A. Global Epidemiology of Mucormycosis. J Fungi. 2019;5:26.

Rawson TM, Moore LSP, Zhu N. Bacterial and fungal co-infection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing. Clin Infect Dis. 2020.

Bottone EJ, Weitzman I HB. Rhizopus rhizopodiformis: emerging etiological agent of mucormycosis. J Clin Microbiol. 1979;9(4):530-7.

Indian Council of Medical Research. Mucormycosis. Available at: www.icmr.gov.in/mucrmycosis/press-release. Accessed on 21 May 2021.

Chennamchetty VK, Adimulapu S, Kola B. Post-COVID pulmonary mucormycosis- A case report. Indian J Immunol Respiratory Med. 2021;6(1):62-6.

Song G, Liang G, Liu W. Fungal co-infections associated with global COVID-19 pandemic: A clinical and diagnostic perspective from China Mycopathologia. 2020;1-8.

White PL, Dhillon R, Cordey A. National strategy to diagnose COVID-19 associated invasive fungal disease in the ICU. Clin Infect Dis. 2020.

Mehta S. Rhino-orbital mucormycosis associated with COVID-19. Cureus. 2020;12(9):e10726.

Griffin KM, Karas M. Available at: NY-PBT/ATSjournals.org. Accessed on 21 May 2021.

Downloads

Published

2022-03-28

How to Cite

Sharma, S., Singhal, M., & Bhandari, S. (2022). Clinical profile of recent progressive illnesses in patients with mucormycosis: a comprehensive analysis. International Journal of Research in Medical Sciences, 10(4), 898–904. https://doi.org/10.18203/2320-6012.ijrms20220983

Issue

Section

Original Research Articles